Drug Profile
Research programme: viral protein inhibitors - GlaxoSmithKline/University of Cambridge
Latest Information Update: 28 Jul 2020
Price :
$50
*
At a glance
- Originator University of Cambridge
- Developer GSK; University of Cambridge
- Class
- Mechanism of Action Viral protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 28 Jul 2020 No recent reports of development identified for research development in HIV-infections in United Kingdom